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Background
The AIDSVAX B/E vaccine used in the RV144 trial con-
sisted of recombinant gp120s derived from the MN and
A244 strains of HIV-1, both produced in CHO cells. In
order to understand the correlates of protection and to
design RV144 follow-up studies, it is important to char-
acterize the vaccine immunogens and to know the
extent to which newly manufactured gp120 subunit vac-
cines replicate the glycosylation of the AIDSVAX B/E
vaccine immunogens. It has long been known that gly-
cosylation affects antigenicity and immunogenicity.
Recent data suggest that several epitopes recognized by
broadly neutralizing antibodies are critically dependent
on glycosylation in the gp120 V2 domain. In these stu-
dies we investigate the heterogeneity in net charge
attributed to glycoform variation.
Methods
Isoelectric focusing was used to analyze recombinant
MN and A244 rgp120 proteins from the unformulated
bulk used to manufacture the AIDSVAX B/E vaccine.
We compared these proteins with MN and A244 rgp120
proteins freshly produced in 293 cells. Differences in the
binding of monoclonal antibodies and soluble CD4 were
measured by ELISA.
Results
MN and A244 rgp120 proteins produced in CHO cells
and 293 cells exhibit extensive heterogeneity in net
charge due to glycosylation. More than 16 species of
MN-rgp120 and 24 species of A244-rgp120 were identi-
fied. Proteins produced in CHO cells were distinctly
more acidic than proteins produced in 293 cells. These
differences affected the binding of ligands that targeted
the CD4 binding site but not other regions of gp120.
Conclusion
The rgp120 proteins used in the RV144 trial exhibited
remarkable variation in net charge attributable to differ-
ences in glycosylation. The extent of gp120 glycosylation
is cell-line dependent. Differences in glycosylation affect
antibody binding and may represent a significant vari-
able in the development of new antigens for RV144 fol-
low-up studies and in neutralization assays that depend
on pseudoviruses produced in 293 cells.
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